bms-1166

BMS-1166 is a potent inhibitor of the PD-1 PD-L1 interaction.

BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride, a resorcinol di-Ph ether scaffold-based programmed cell death-1 (PD-1) programmed cell death ligand 1 (PD-L1) inhibitor, inhibits the PD-1 PD-L1 interaction with an IC50 of 39.2 nM. It contains the target protein PD-1 PD-L1 ligand and PROTAC linker, which can be used to synthesize PROTAC PD-1 PD-L1 degrader-1 and has anticancer activity. Additionally, it serves as a diluent for the preparation of tablets for direct compression.

BMS-1166-N-piperidine-COOH is a chemical compound that functions as the BMS-1166-based moiety. It binds to the E3 ligase ligand through a linker, leading to the formation of PROTAC PD-1/PD-L1 degrader-1, which facilitates the degradation of PD-1/PD-L1. BMS-1166 demonstrates potent inhibition of PD-1/PD-L1 interaction, with an IC 50 of 1.4 nM. By antagonizing the inhibitory effect of the PD-1/PD-L1 immune checkpoint on T cell activation, BMS-1166 promotes T cell activation.

Motixafortide (BKT140 4-fluorobenzoyl) is an antagonist of CXCR4 (IC50: 1 nM). BMS-1166 hydrochloride is an inhibitor of PD-1 PD-L1 interaction (IC50: 1.4 nM). BMS-1166 rivalries the inhibitory effect of PD-1 PD-L1 immune checkpoint on T cell activation.

BMS-1166-N-piperidine-CO-N-piperazine is a chemical compound containing a PD-1 PD-L1 immune checkpoint ligand and a PROTAC linker. It is used in synthesizing [PROTAC PD-1 PD-L1 degrader-1], which effectively inhibits the PD-1 PD-L1 interaction with an IC50 value of 39.2 nM.